BSE filing, NSE: SPARC. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharma Advanced Research Company Ltd: key numbers
- Share price
- ₹176.46
- Market cap
- ₹5,727 Cr
- Revenue (annual)
- ₹1,879 Cr
- Net profit (annual)
- ₹1,553 Cr
- P/E (TTM)
- 3.6×Sector 45.9×
- Promoter holding
- 65.67%+0.00% QoQ
- FII holding
- 3.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharma Advanced Research Company Ltd
All →Sun Pharma Advanced Research Company Board Meeting Date
SPARC intimated its Board will meet November 2, 2026 to consider Q1 and H1 FY27 unaudited results. Insider trading window stays closed until 48 hours post-declaration.
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sun Pharma Advanced Research Company Legal & Regulatory
The company secured a favorable CESTAT order confirming its entitlement to a Rs. 27.51 Crore CENVAT credit refund. This concludes the litigation in the company's favor.
- Value
- ₹27.51 Cr
Sun Pharma Advanced Research Company Other Announcement
Sun Pharma Advanced Research Company Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026.
Sun Pharma Advanced Research Company Promoter Reclassification
Sun Pharma Advanced Research Company has submitted an application to stock exchanges to reclassify certain members from 'Promoter Group' to 'Public' category.
Sun Pharma Advanced Research Company Annual General Meeting
SPARC held its 21st Annual General Meeting on August 10, 2026, via video conferencing. The meeting covered routine business, including adoption of financial statements.
Other adverse business impact announcements
All →Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr
Hindustan Organic Chemicals Adverse Business Impact
Hindustan Organic Chemicals temporarily shuts down its Kochi Hydrogen plant from 29 October 2026 for pipeline repair and urgent maintenance. Reopening date to be communicated separately.
IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.
Ecoboard Industries Adverse Business Impact
Ecoboard suspended its Particle Board division for one year over raw material shortages and non-viability. Venkatraman Krishnamurthi was appointed CEO, while Gottumukkala steps down to MD.
- Execution
- One (1) year temporary suspension